Health by Tiffany Bakker
Premium Content  We re on a first-name basis with the AstraZeneca vaccine and we know all about Pfizer and, if you have family overseas, chances are you ve heard about Moderna and Johnson & Johnson. But how many new COVID-19 vaccines are in development, when will they be ready for use and just how will we take them? Â
HOW MANY COVID VACCINES ARE IN DEVELOPMENT? According to the World Health Organisation, there are currently 277 coronavirus vaccines in development globally, of which 93 have entered the human testing phase. Most of the vaccines in clinical testing are administered as an injection, but there are two which can be taken orally and seven nasal-spray formulations.
World s next COVID vaccines: What s being trialled dailymercury.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymercury.com.au Daily Mail and Mail on Sunday newspapers.
Lazard, Allens test interest in Aussie lab services play 360Biolabs
Save
Share
Australian laboratory services provider 360Biolabs is seeking to capitalise on red-hot demand for biotech research testing companies and their service providers.
360Biolabs provides laboratory services to clinical research organisations, helping to test and develop the next wave of therapeutics, vaccinations and diagnostic tools.Â
Stuart Layt
Street Talk can reveal 360Biolabs, which is based in Melbourne and makes $20 million EBITDA a year, has called in bankers at Lazard to pitch the business to potential buyers in Australia and offshore.
It is understood Lazard has sent a sale flyer, outlining 360Biolabs and its investor search, to deep-pocketed private equity firms and large biotech players to kick off an auction. Law firm Allens is also involved, sources said.
Last modified on Thu 22 Apr 2021 23.01 EDT
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial from June to September proposes using genetic modification to prevent the virus multiplying and insert a gene encoding the Sars-Cov-2 spike protein to help people produce antibodies against Covid-19.
A health department spokesman said the trial related to a vaccine that was “new to Australia” and was sponsored by Tetherex. It is seeking men and women aged 18 to 55 with no history of blood clot disorders.
Study shows clamp technology promising for future vaccine development pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.